Fingerprint
Dive into the research topics of 'RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically